DAMORA THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Assets
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Other Noncurrent Assets of $23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$837.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $295.00K, a 152.14% increase year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-06-30 was $225.00K, a 18.18% decline year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was $151.00K, a 74.05% decline year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was -$166.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was -$970.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was -$1.15M, a 546.69% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was $257.00K, a 70.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.00K 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | -$837.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$542.00K derived: sum of 2 quarters · filed 2026-03-19 | -$317.00K derived: sum of 3 quarters · filed 2026-08-10 | -$166.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $520.00K derived: sum of 2 quarters · filed 2026-08-10 | $671.00K 10-Q · filed 2025-11-06 | -$1.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $376.00K 10-Q · filed 2026-08-10 | -$1.57M derived: sum of 3 quarters · filed 2026-08-10 | -$1.45M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $151.00K 10-Q · filed 2026-05-12 | -$1.79M derived: sum of 2 quarters · filed 2026-05-12 | -$1.68M derived: sum of 3 quarters · filed 2026-05-12 | -$1.40M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.83M derived: sum of 2 quarters · filed 2026-03-19 | -$1.55M derived: sum of 3 quarters · filed 2026-03-19 | -$970.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $392.00K derived: sum of 2 quarters · filed 2025-11-06 | $974.00K 10-Q · filed 2025-11-06 | -$315.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $857.00K 10-Q · filed 2025-08-05 | -$432.00K derived: sum of 3 quarters · filed 2025-08-05 | -$494.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $582.00K 10-Q · filed 2025-05-08 | -$707.00K derived: sum of 2 quarters · filed 2025-05-08 | -$769.00K derived: sum of 3 quarters · filed 2025-05-08 | -$778.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$1.35M derived: sum of 2 quarters · filed 2025-03-19 | -$1.36M derived: sum of 3 quarters · filed 2025-03-19 | -$1.15M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$71.00K derived: sum of 2 quarters · filed 2024-11-01 | $141.00K 10-Q · filed 2024-11-01 | -$387.00K derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $203.00K 10-Q · filed 2024-08-12 | -$325.00K derived: sum of 3 quarters · filed 2024-08-12 | -$521.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $212.00K 10-Q · filed 2024-04-29 | -$316.00K derived: sum of 2 quarters · filed 2024-04-29 | -$512.00K derived: sum of 3 quarters · filed 2024-04-29 | -$301.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | -$528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$724.00K derived: sum of 2 quarters · filed 2024-03-08 | -$513.00K derived: sum of 3 quarters · filed 2024-03-08 | $257.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $15.00K derived: sum of 2 quarters · filed 2023-11-06 | $785.00K 10-Q · filed 2023-11-06 | $1.45M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $981.00K 10-Q · filed 2023-07-31 | $1.64M derived: sum of 3 quarters · filed 2023-07-31 | $1.01M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $770.00K 10-Q · filed 2023-04-28 | $1.43M derived: sum of 2 quarters · filed 2023-04-28 | $795.00K derived: sum of 3 quarters · filed 2023-04-28 | $814.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $25.00K derived: sum of 2 quarters · filed 2023-03-09 | $44.00K derived: sum of 3 quarters · filed 2023-03-09 | $866.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$638.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$619.00K derived: sum of 2 quarters · filed 2022-11-08 | $203.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $841.00K 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | $822.00K 10-Q · filed 2022-04-29 | |||
| 2020-12-31 | $1.16M 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |